- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Gw Pharmaceuticals Share News (GWP)
Share News for Gw Pharmaceuticals (GWP)
| Share Price: 49.25 | Bid: 48.50 | Ask: 50.00 | Change: 0.00 (0.00%) |  | ||||||
| ||||||||||
BRIEF-GW Pharma wins U.S. patent for Sativex in cancer pain
Wed, 20th Apr 2011 07:20
LONDON, April 20 (Reuters) - GW Pharmaceuticals PLC:
* US patent granted for Sativex in c
* Sativex is currently in Phase III clinical development as a treatment for cancer pain
* Cancer pain represents the lead indication for Sativex in the United States, where the medicine is partnered with Otsuka Pharmaceutical Co. Ltd. ((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
LONDON, April 20 (Reuters) - GW Pharmaceuticals PLC:
* US patent granted for Sativex in c
ancer pain
* Sativex is currently in Phase III clinical development as a treatment for cancer pain
* Cancer pain represents the lead indication for Sativex in the United States, where the medicine is partnered with Otsuka Pharmaceutical Co. Ltd. ((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2011. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
STOCKS NEWS EUROPE-UK small caps advance 0.2 percent
UK small caps rise 0.2 percent, while the blue chips climb 0.3 percent, and the midcaps are 0.1 percent higher.GW Pharmaceuticals adds 7.5 percent aft[7 May '13]
UPDATE 1-GW, Almirall may pull cannabis drug in German price row
* Germany refuses to pay "acceptable" price for Sativex* Almirall to challenge price decision, may withdraw supply* GW Pharmaceuticals aims to list sh[19 Mar '13]
Journal questions use of cannabis spray drug for MS
LONDON, Dec 13 (Reuters) - There is little evidence to back the use of a cannabis extract spray made by GW Pharmaceuticals for spasticity in pa[12 Dec '12]
BRIEF-GW Pharma Sativex study shows MS spasticity benefits
LONDON, Oct 12 (Reuters) - GW Pharmaceuticals PLC: * Positive German sativex data presented at ectrims * confirms clinically relevant[12 Oct '12]
BRIEF-GW Pharma appoints Chris Tovey COO
LONDON, Oct 1 (Reuters) - GW Pharmaceuticals PLC: * Appointment of chief operating officer ((London Equities Newsroom; +44 20 7542 77[1 Oct '12]
Drug firm GW to test cannabis chemical in epilepsy
LONDON, Sept 13 (Reuters) - A British drug company aims to test a compound found in cannabis as a treatment for epilepsy, following a promising[13 Sep '12]
BRIEF-GW Pharma's Sativex gets German boost
LONDON, June 22 (Reuters) - GW Pharmaceuticals PLC: * German G-BA establishes positive additional benefit of Sativex in Multiple Sclerosis[22 Jun '12]
BRIEF-GW Pharma's Sativex set for approval in 10 countries
LONDON, May 8 (Reuters) - GW Pharmaceuticals PLC: * Pharma - sativex mutual recognition procedure closes with recommendation for ap[8 May '12]
